Parkinson’s disease (PD) affects an estimated 10 million people worldwide, including more than 1.1 million in the United States. With prevalence rising as the population ages, experts warn of a growing public health crisis and an economic burden that exceeds...
Expertise: Neuroscience 45 results
Neuroscience
Raising the Bar in Global MDD Research
Neuroscience
Jennifer Stewart
In CNS trials, inconsistent endpoint assessments can jeopardize outcomes. Premier Research offers customized rater training to reduce variability, minimize placebo response, and improve data quality from the start. Powered by our Remarque™ platform, we deliver real-time monitoring, centralized scoring, and...
The Alzheimer’s research landscape is undergoing a fundamental transformation. With disease-modifying therapies now a reality, sponsors must rethink how they design, recruit for, and execute trials—particularly in early-stage and preclinical populations. This guide explores five strategic imperatives that can help...
For decades, the Alzheimer’s disease (AD) treatment landscape remained largely static, focused on symptom management rather than disease modification. But in recent years, the field has entered a transformational period. With the emergence of new biomarkers, approval of novel anti-amyloid...
Neuroscience
Dr. Martin Strassnig
Neuroscience
Melissa Snyder, Ph.D.
Neuroscience
Gladys Valdez, Ph.D.
In central nervous system (CNS) clinical trials, the integrity of clinician- and patient-reported outcomes is essential to generating reliable, high-quality data. Given the complexity of neurological disorders and the subjective nature of key endpoints, even small inconsistencies in assessment administration...